47 completed, 22 active not recruiting, 10 recruiting, 10 terminated. 55 Phase 2, 41 Phase 1, 6 Phase 3, 2 Early Phase 1, 2 Not applicable.
Follow Recurrent Primary Peritoneal Carcinoma: new trials by email Literature Review of Recurrent Primary Peritoneal Carcinoma trials Research Report on Recurrent Primary Peritoneal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study Behavioral Intervention, Best Practice, Biospecimen Collection - Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Not applicable | Recruiting | Roswell Park Cancer Institute | 120 | 2025-06-04 | 2026-01-06 |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Biopsy, Biospecimen Collection, Niraparib - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-18 | 2025-05-23 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study Non-Interventional Study - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Recruiting | University of Washington | 2000 | 2024-01-02 | 2026-04-17 | |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 165 | 2023-04-25 | 2026-10-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-10-15 |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lenvatinib, Paclitaxel, Pembrolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Floor Backes, MD | 38 | 2021-09-01 | 2026-10-21 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Abexinostat Tosylate, Fulvestrant, Palbociclib - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Pamela Munster | 2021-03-31 | 2021-05-18 | |
| Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Pembrolizumab, Computed Tomography - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | University of Washington | 22 | 2021-03-18 | 2026-06-29 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer Abemaciclib, Anastrozole, Letrozole - Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 32 | 2020-10-16 | 2026-07-17 |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | Ira Winer | 62 | 2020-01-21 | 2026-06-17 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 61 | 2019-12-04 | 2026-08-26 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
Showing 20 of 99. Sign in to see all of them.
Fallopian Tube Neoplasms (99) · Ovarian Neoplasms (96) · Endometrial Neoplasms (10) · Brenner Tumor (9) · Breast Neoplasms (8) · Triple Negative Breast Neoplasms (5) · Neoplasm Metastasis (3) · Uterine Cervical Neoplasms (3) · Carcinosarcoma (2) · Fatigue (2) · Mesothelioma, Malignant (2) · Neoplasms (2) · Neurotoxicity Syndromes (2) · Peritoneal Neoplasms (2) · Vaginal Neoplasms (2)
Adnexal Diseases (99) · Fallopian Tube Diseases (99) · Female Urogenital Diseases (99) · Female Urogenital Diseases and Pregnancy Complications (99) · Genital Diseases (99) · Genital Diseases, Female (99) · Genital Neoplasms, Female (99) · Neoplasms by Site (99) · Urogenital Diseases (99) · Urogenital Neoplasms (99) · Endocrine Gland Neoplasms (97) · Endocrine System Diseases (97) · Gonadal Disorders (97) · Neoplasms (97) · Ovarian Diseases (97)
Disulfides (17) · Immunoglobulin G (17) · Paclitaxel (17) · Taxes (17) · Bevacizumab (14) · Specimen Handling (13) · Carboplatin (12) · Magnetic Resonance Spectroscopy (12) · Doxorubicin (11) · Gemcitabine (10) · liposomal doxorubicin (10) · olaparib (9) · pembrolizumab (9) · Biopsy (6) · veliparib (6)
National Cancer Institute (NCI) (34) · M.D. Anderson Cancer Center (10) · Mayo Clinic (10) · Roswell Park Cancer Institute (9) · Gynecologic Oncology Group (8) · City of Hope Medical Center (4) · GOG Foundation (3) · Jonsson Comprehensive Cancer Center (3) · University of Washington (3) · Northwestern University (2) · Albert Einstein College of Medicine (1) · Barbara Ann Karmanos Cancer Institute (1) · Corcept Therapeutics (1) · ECOG-ACRIN Cancer Research Group (1) · Floor Backes, MD (1)
United States (93) · Canada (7) · Puerto Rico (4) · South Korea (4) · Japan (3) · Belgium (1) · Italy (1) · Netherlands (1) · Singapore (1) · Spain (1)
Emese Zsiros (6) · Amir A Jazaeri (3) · Shannon N Westin (3) · Andrea E Wahner Hendrickson (2) · Bradley J Monk (2) · Emese Zsiros, MD (2) · Floor Backes, MD (2) · Gerardo Colon-Otero (2) · Joyce F Liu (2) · Kunle Odunsi (2) · Lilie L Lin (2) · Matthew S. Block, M.D., Ph.D. (2) · Amir Jazaeri (1) · Amit M Oza (1) · Amit Oza (1)
PMID 37185961, PMID 32379297, PMID 25318437, PMID 25488966, PMID 27217446, PMID 28341300, PMID 28438473, PMID 29242937, PMID 30309721, PMID 30587441, PMID 31722153, PMID 32553118, PMID 33109627, PMID 33211063, PMID 33485453, PMID 34531249, PMID 35007153, PMID 35170751, PMID 35290101, PMID 35357903, PMID 35671108, PMID 37364223, PMID 37702588, PMID 38009662, PMID 38471508, PMID 38635934, PMID 39208372, PMID 39361946, PMID 39638782, PMID 40051286, PMID 40685312, PMID 40839922, PMID 41289795, PMID 41528970
U10CA180868 (23), U10CA027469 (17), UM1CA186709 (5), P30CA015083 (4), N01CM00032 (3), N01CM00038 (3), N01CM00071 (3), P30CA006516 (3), P30CA016056 (3), P50CA136393 (3), N01CM00099 (2), N01CM62201 (2), N01CM62203 (2), N01CM62204 (2), N01CM62208 (2)